Abingworth’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Abingworth’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-337,825	Closed	-$973K	–	18
2016 Q4	$973K	Sell	337,825 -607,932	-64%	-$2.16M	0.81%	16
2016 Q3	$5.56M	Hold	945,757	–	–	5.33%	6
2016 Q2	$2.83M	Hold	945,757	–	–	2.96%	9
2016 Q1	$5.06M	Hold	945,757	–	–	4.7%	6
2015 Q4	$11.2M	Hold	945,757	–	–	6.77%	6
2015 Q3	$7.75M	Hold	945,757	–	–	4.53%	7
2015 Q2	$13.2M	Sell	945,757 -26,977	-3%	-$495K	5.98%	7
2015 Q1	$23.4M	Sell	972,734 -209,462	-18%	-$4.71M	9.93%	4
2014 Q4	$19.4M	Hold	1,182,196	–	–	5.52%	8
2014 Q3	$15M	Hold	1,182,196	–	–	8.99%	5
2014 Q2	$26.7M	Hold	1,182,196	–	–	12.4%	4
2014 Q1	$33.3M	Buy	+1,182,196	New	+$43.9M	18.38%	2

Other funds holding DRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Abingworth's DRNA Position: Q1 2017 in Review

Abingworth sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2017, closing a stake of 337,825 shares — an estimated $973K sold.

Abingworth first reported a position in DRNA in Q1 2014 and held it in 12 quarters. The position peaked at $33.3M in Q1 2014. 45 funds tracked by Wall St. Rank hold DRNA as of Q1 2017.

Abingworth reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Abingworth sold 337,825 Dicerna Pharmaceuticals, Inc. shares in Q1 2017, an estimated $973K.
Abingworth first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and held it in 12 quarters.
Abingworth's Dicerna Pharmaceuticals, Inc. position peaked at $33.3M in Q1 2014.
45 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2017.

Based on Abingworth's 13F filing for Q1 2017, filed 15 May 2017.